Saturday, May 28, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



Iranian vaccine against Omicron concludes effective clinical trials

Irán, vacuna, COvid-19, Omicron, ensayos, clínicos, conclusión

Iranian vaccine against Omicron concludes effective clinical trials

Tehran, Feb 17 (Prensa Latina) An Iranian pharmaceutical company has concluded the clinical trials in animals of a vaccine against the Omicron SARS-CoV-2 variant with 100 percent effectiveness, a health communique reported on Thursday.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The announcement of the new vaccine, focused on the highly contagious Covid-19 variant, was made by Iran’s Shifa Pharmed Industrial Group, which has produced the home-grown COVIran Barekat vaccine against the coronavirus, the first immunizer in Iran to fight Covid-19.

Shifa Pharmed also announced the presentation of the protocol to the Iranian Food and Drug Administration, in order to obtain the necessary permits.

Iran currently has more than 80 percent of its population fully vaccinated, enabling it to deal more effectively with the sixth wave of contagions, which is being driven by Omicron.

The country announced its first vaccine in June 2021 and shortly thereafter, it added the Soberana 02 vaccine, jointly developed by Iran and Cuba.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.